EUVIMEDEUVIMED entdecken
Crossref

Prediagnostic use of menopausal hormone therapy and long‐term survival of localized epithelial ovarian cancer: The Extreme study

Alberte Hjorth Duus iD, Charlotte Gerd Hannibal iD, Louise Baandrup iD, Guoqiao Zheng iD, Michael Galanakis, Thomas Maltesen, Rasmus Hertzum-Larsen, Lina S Mørch, Susanne K Kjær

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Alberte Hjorth Duus und 8 weiteren Autor:innen. Beteiligte Einrichtung: Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: MERMAID Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Use of menopausal hormone therapy (MHT) prior to an epithelial ovarian cancer (EOC) diagnosis has been suggested to be associated with improved survival. In a recent nationwide cohort study, we found that prediagnostic long‐term MHT use, especially estrogen therapy (ET), was associated with improved long‐term survival in women with nonlocalized EOC. Our aim was to investigate the influence of prediagnostic MHT use on long‐term survival among women with localized EOC in the same nationwide study. Our study cohort comprised all women aged 50 years or older with an EOC diagnosis in Denmark 2000–2014 ( n = 2097) identified from the Extreme study. We collected information on usage of systemic ET and estrogen plus progestin therapy (EPT) from the Danish National Prescription Registry. By using pseudo‐values, 5‐ and 10‐year absolute and relative survival probabilities were estimated with 95% confidence intervals (CIs) while adjusting for histology, comorbidity, and income. Relative survival probabilities >1 indicate better survival. The 5‐year absolute survival probabilities were 61% and 56%, respectively, among women who were nonusers and users of prediagnostic MHT, whereas these numbers were 46% and 41%, respectively, regarding 10‐year survival. Use of MHT was not significantly associated with an improved 5‐ or 10‐year survival in women with localized EOC (5‐year relative survival probability = 0.95, 95% CI: 0.89–1.02; 10‐year relative survival probability = 0.92, 95% CI: 0.84–1.02). Similar findings were seen for systemic ET or EPT use. Our findings do not suggest a positive benefit from prediagnostic MHT use on long‐term survival of localized EOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Ovarian EpithelialOvarian NeoplasmsHumansFemaleMiddle AgedDenmarkAgedEstrogen Replacement TherapyRegistriesCohort StudiesMenopauseEstrogensProgestins

Stichwörter der Autor:innen

long‐term survivalmenopausal hormone therapyovarian cancer

Substanzen

EstrogensProgestins

Autor:innen und Institutionen

  • Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Pathology, Zealand University Hospital, Roskilde, Denmark.
  • Statistics and Data Analysis, Danish Cancer Institute, Copenhagen, Denmark.
  • Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Institute, Copenhagen, Denmark.
  • Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Alberte Hjorth Duus, Charlotte Gerd Hannibal, Louise Baandrup, Guoqiao Zheng

Förderung

  • MERMAID Project

Zitieren

APA

Duus, A. H., Hannibal, C. G., Baandrup, L., Zheng, G., Galanakis, M., Maltesen, T., Hertzum-Larsen, R., Mørch, L. S., & Kjær, S. K. (2024). Prediagnostic use of menopausal hormone therapy and long‐term survival of localized epithelial ovarian cancer: The Extreme study. International Journal of Cancer. https://doi.org/10.1002/ijc.34936

Vancouver

Duus AH, Hannibal CG, Baandrup L, Zheng G, Galanakis M, Maltesen T, et al. Prediagnostic use of menopausal hormone therapy and long‐term survival of localized epithelial ovarian cancer: The Extreme study. International Journal of Cancer. 2024. doi:10.1002/ijc.34936

BibTeX
@article{Duus2024,
  author = {Duus, Alberte Hjorth and Hannibal, Charlotte Gerd and Baandrup, Louise and Zheng, Guoqiao and Galanakis, Michael and Maltesen, Thomas and Hertzum-Larsen, Rasmus and Mørch, Lina S and Kjær, Susanne K},
  title = {Prediagnostic use of menopausal hormone therapy and long‐term survival of localized epithelial ovarian cancer: The Extreme study},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34936}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche